Business Context and Reporting Period
This Form 8-K is filed by Sema4 Holdings Corp. (Note: Request metadata referenced "Genedx Holdings Corp.", but the filing text identifies the registrant as Sema4 Holdings Corp.) for the reporting period of October 14, 2021, covering an event dated October 8, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in Stamford, Connecticut.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the departure of James Coffin, Ph.D., from his active duties as President and Chief Operating Officer (COO). Dr. Coffin, who also served as Treasurer from January to March 2021, is taking a short-term disability leave for medical reasons commencing in October 2021 for approximately 90 days.
Guidance, Outlook, and Management Commentary
- Interim Leadership: During Dr. Coffin's leave, the Chief Financial Officer, Isaac Ro, and the Chief Business Officer, Kareem Saad, will assume the functions previously performed by Dr. Coffin.
- Operational Impact: Management states it does not anticipate that the leave will adversely impact the Company's financial performance, timelines for corporate objectives, research and development progress, or strategic partnerships.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to Dr. Coffin's medical condition and other uncertainties identified in prior SEC filings.
Investor Verification Checklist
- Verify the exact start date of Dr. Coffin's leave and the specific duration beyond the estimated 90 days.
- Confirm the specific division of duties between Isaac Ro and Kareem Saad regarding Dr. Coffin's former responsibilities.
- Review subsequent filings to ensure the leave does not extend beyond the initial estimate or impact key R&D milestones.
- Check for any changes in the Company's strategic partnerships or collaborations that may arise during this interim period.